Skip to content

Study · Observational study · 2026

4 results

Development of Muscle Function in Children with Achondroplasia Under Vosoritide Treatment: A Retrospective Single-Centre Observational Study.

Reincke S, Stasek S, Junghänel-Welzing S, Semler O, Rehberg M, Duran I, Hoyer-Kuhn H

Journal of musculoskeletal & neuronal interactions1 Mar 2026

PMID41764752 (opens in a new tab)PMCIDPMC12952509 (opens in a new tab)PepBankPUB-41764752
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with achondroplasia, vosoritide treatment was linked to increased height z-scores over 36 months versus baseline (p < 0.001).

    In plain wordsIn children with achondroplasia, vosoritide treatment was linked to higher height z-scores than baseline.

    Peptide
    Vosoritide
    Outcome
    IncreaseHeight z-score
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Vosoritide treatment resulted in significant gains in height z-scores over 36 months (p < 0.001).
    2 context sentences
    Summary · context
    Nineteen (19) children with achondroplasia treated with vosoritide for at least 12 months were included.
    Summary · context
    Muscle function was assessed via two-legged jump tests on a ground reaction force plate at baseline, month 12, 24 and 36.
  2. 02HumanObservational studyEfficacy outcome

    In children with achondroplasia, raw jumping parameters increased numerically during vosoritide treatment, except relative force.

    In plain wordsIn children with achondroplasia, raw jumping measures increased numerically during vosoritide treatment, except relative force.

    Peptide
    Vosoritide
    Outcome
    IncreaseRaw jumping parameters
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Raw values of jumping parameters increased numerically over time for all parameters except relative force; however, no significant changes were observed in z-scores.
    2 context sentences
    Summary · context
    Nineteen (19) children with achondroplasia treated with vosoritide for at least 12 months were included.
    Summary · context
    Muscle function was assessed via two-legged jump tests on a ground reaction force plate at baseline, month 12, 24 and 36.
  3. 03HumanObservational studyEfficacy outcome

    In children with achondroplasia, vosoritide treatment was not linked to significant changes in jumping parameter z-scores versus baseline.

    In plain wordsIn children with achondroplasia, jumping parameter z-scores did not change significantly from baseline during vosoritide treatment.

    Peptide
    Vosoritide
    Outcome
    No significant changeJumping parameter z-scores
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Raw values of jumping parameters increased numerically over time for all parameters except relative force; however, no significant changes were observed in z-scores.
    2 context sentences
    Summary · context
    Nineteen (19) children with achondroplasia treated with vosoritide for at least 12 months were included.
    Summary · context
    Muscle function was assessed via two-legged jump tests on a ground reaction force plate at baseline, month 12, 24 and 36.
  4. 04HumanObservational studyEfficacy outcome

    In children with achondroplasia, walking distances did not change significantly during vosoritide treatment versus baseline.

    In plain wordsIn children with achondroplasia, walking distances did not change significantly from baseline during vosoritide treatment.

    Peptide
    Vosoritide
    Outcome
    No significant changeSix-minute walking distance
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Exploratory
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, no significant changes were detected in 6-minute walking distances.
    2 context sentences
    Summary · context
    Nineteen (19) children with achondroplasia treated with vosoritide for at least 12 months were included.
    Summary · context
    Muscle function was assessed via two-legged jump tests on a ground reaction force plate at baseline, month 12, 24 and 36.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.